<DOC>
	<DOC>NCT00401284</DOC>
	<brief_summary>The purpose of this study is to determine whether a compound known as EVT 201 is effective in treating elderly patients diagnosed with primary insomnia who also have moderate daytime sleepiness.</brief_summary>
	<brief_title>Efficacy Study of EVT 201 in the Treatment of Elderly Patients With Daytime Sleepiness</brief_title>
	<detailed_description />
	<mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
	<criteria>Diagnosis of primary insomnia according to DSMIV Over the last three months for at least 5 nights per week, must have a normal bedtime of between 9 pm and 1 am and a time in bed of at least 7 hours A history of sleepiness, tiredness or unintentional napping during the daytime attributed to to poor sleep at night Able to attend the Sleep Center for five nights (two consecutive nights on two occasions and one night on one occasion)over a five week period Willing and able to complete a sleep diary and questionnaires Clinically significant or unstable medical condition that may interfere with sleep Major psychiatric disorders (other than insomnia) such as depression, schizophrenia, bipolar disorder History of myocardial infarction, cardiac failure or clinically significant dysrhythmias in the previous 2 years or clinically significant ECG abnormalities at screening History of substance abuse Disorders that interfere with drug pharmacokinetics History of cancer, except basal cell carcinoma Use of hypnotics, anxiolytics, antidepressants, anticonvulsants, overthecounter sleep aids, histamine1 receptor antagonists (except for loratadine and fexofenadine), betaadrenergic blockers (except for atenolol), respiratory stimulants and decongestants, systemic steroids, narcotic analgesics, any other compound which might impact sleepwake function, or medication used for the treatment of Parkinson's disease such as dopamine agonists and Ldopa (e.g., Sinemet, Madopar or Requip) Use of hypnotics within the 2 weeks preceding the Screening Period or within five halflives of the medication, whichever is longer Consuming ≥ 350 mg per day of xanthinecontaining food or beverages Smoking ≥ 10 cigarettes per day and/or unable to refrain from smoking without distress or discomfort for the duration of visits to the sleep laboratory (i.e.≥ 20 hours) Body mass index &gt; 34 kg/m2; Performing night work or rotating shift work during the past month Traveling across &gt; 3 time zones in the past 2 weeks Participation in another trial of an investigational product or device within the previous 30 days Known allergy or sensitivity to benzodiazepines</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
</DOC>